DepYmed Inc., is a New York based cancer and rare disease therapeutic development company that was founded to capitalize on the scientific discoveries of the Tonks lab in PTP1B (protein tyrosine phosphatase 1B) signaling and ways to modulate its role in various human diseases. DepYmed is currently developing a new class of potent, orally bioavailable inhibitors of the PTP1B enzyme as potential novel therapeutics for different types of cancer and Rett Syndrome. In addition, DepYmed has also discovered a novel class of small molecules with copper chelating properties that it is developing as potential therapeutic agents for diseases like Wilson Disease and various cancers. The company is actively developing a deep pipeline of new compounds in these emerging drug classes in collaboration with Cold Spring Harbor Laboratory to exploit their broad therapeutic potential.
